Thiazolidinediones News and Research

RSS

Thiazolidinediones are adjunctive therapies for diabetes mellitus (type 2) and related diseases.

New understanding of the link between heart disease and belly fat

By now, everyone knows that overweight people have a higher risk of heart attacks, strokes and other problems that arise from clogged, hardened arteries. And people who carry their extra weight around their waist - giving them a "beer belly" or an "apple" shape - have the highest risk of all.

22 Jan 2008

Takeda submits NDA for Alogliptin (SYR-322) in the U.S.

Takeda Pharmaceutical Company Limited (Takeda) has announced that Takeda Global Research & Development Center, Inc. submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for alogliptin (development code: SYR-322), a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes.

7 Jan 2008

Use of thiazolidinediones by seniors linked with increased risk of heart problems

Older patients treated with the diabetes medications known as thiazolidinediones (which include rosiglitazone) had a significantly increased risk of heart attack, congestive heart failure and death, compared with the use of other hypoglycemic drugs, according to a study in the December 12 issue of JAMA.

13 Dec 2007

Study finds Avandia may increase risk of heart failure

A popular class of drugs for treating type 2 diabetes is under scrutiny again. A new Canadian study released by the Institute for Clinical Evaluative Sciences (ICES) finds that drugs such as Avandia increase the risk of heart failure, heart attacks and death.

13 Dec 2007

GlaxoSmithKline response to JAMA article on ICES retrospective analysis

The following is GlaxoSmithKline's response to the retrospective analysis by the Institute for Clinical Evaluative Sciences (ICES) titled "Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes".

13 Dec 2007

Rosiglitazone and Pioglitazone increase risk of congestive heart failure but not the risk of cardiovascular death

Patients with type 2 diabetes* or prediabetes* are more likely to develop congestive heart failure (CHF) when given rosiglitazone or pioglitazone, as compared with controls. However these drugs did not increase the risk of cardiovascular death (CVD) for these patients.

1 Oct 2007

Discovery may lead to new class of diabetes drugs

A multidisciplinary team led by researchers at the University of California, San Diego has determined the structure of a protein found in cells that shows potential as a target for the development of new drugs to treat diabetes.

30 Aug 2007

Caution urged on use of drugs to raise "good" cholesterol

With 40 percent of all heart attacks and related cardiovascular problems occurring in people who have low levels of so-called "good" cholesterol, researchers have long sought medications to increase the amount of this type of cholesterol in the body's circulation.

16 Aug 2007

Takeda responds to FDA recommendation on Actos

Following a joint meeting today of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Takeda Global Research & Development (TGRD) underscores its position that ACTOS(R) (pioglitazone HCl) offers a proven safety profile regarding the risk of cardiovascular disease.

30 Jul 2007

Avandia too risky says expert

One of the members of the advisory panel set up to discuss the future of the diabetes pill Avandia says it should be removed from the market because it is too risky and offers no advantage over other alternatives.

30 Jul 2007

Metformin gets top grade for diabetes

A type 2 diabetes drug taken orally and in widespread use for more than a decade has been found to have distinct advantages over nine other, mostly newer medications used to control the chronic disease, according to a study by researchers at Johns Hopkins.

26 Jul 2007

Plant chemical harmine fights diabetes in mice

After screening hundreds of compounds for their effects on fat development, researchers have discovered that an ingredient found in some plants fights diabetes in mice without some of the side effects attributed to other antidiabetes drugs.

9 May 2007

Pioglitazone may help slow progression of artery wall thickening

A medication given to diabetics to improve their body's sensitivity to insulin also appears to slow the thickening of their artery walls, according to a study posted online by JAMA: The Journal of the American Medical Association.

13 Nov 2006

Thiazolidinediones may reduce cardiovascular risks

A drug commonly used to increase the body's sensitivity to insulin may slow the progression of cardiovascular disease in patients with type 2 diabetes, according to a study at the University of Illinois at Chicago College of Medicine.

13 Nov 2006

New diabetes drug Januvia works without causing weight gain

The Food and Drug Administration (FDA) in the U.S. has granted approval for a new drug to treat adults with type 2 diabetes.

17 Oct 2006

Alzheimer's disease linked to raised blood sugar levels

Researchers at an Alzheimer's Conference in Spain have come up with more information on the disease and just who amongst the population is most likely to get it.

17 Jul 2006

Latest diabetic medications more costly, but users have fewer hospital visits

Diabetics who were prescribed newer medications to control their illness were more likely to take these drugs as instructed than were other patients who were prescribed drugs that have been on the market for several decades.

22 Mar 2006

Study reveals mechanisms behind Thiazolidinediones used to treat type 2 diabetes

Thiazolidinediones (TZD's) are drugs commonly prescribed to patients with type 2 diabetes, the most common form of diabetes. Current U.S. Food and Drug Administration-approved agents are known as Actos (pioglitazone) and Avandia (rosiglitazone).

13 Mar 2006

Scientists have discovered how C-reactive protein is able to access endothelial cells

For the first time, scientists have discovered how C-reactive protein, or CRP, is able to access endothelial cells. The UC Davis researchers' findings will be published in the July issue of Arteriosclerosis, Thrombosis, and Vascular Biology, one of the American Heart Association's leading journals.

27 Jun 2005

Insulin resistance drug with anti-inflammatory effects reduces risk factors

A drug, which reduces insulin resistance and also may have anti-inflammatory and other effects on blood vessels, lowered cardiovascular risk factors in patients with diabetes more than another diabetes medicine, even though both drugs improved blood sugar control equally, according to a new study (PDF) in the June 21, 2005, issue of the Journal of the American College of Cardiology.

21 Jun 2005